With an intense, singular focus, Aminex has advanced AMXT 1501+ DFMO through target discovery, patenting, pre-clinical research and now into clinical development for the potential benefit of cancer patients.

Aminex Therapeutics is led by an experienced management team and board of directors. The company has received backing of approximately $29 million since inception from a passionate, committed group of private investors.